Implication of Integrin ?5?1 in right ventricular failure associated with pulmonary arterial hypertension - Vienna 2024

Novel aspects in pulmonary hypertension

Chair(s): Jurjan Aman, Laura Price

Session type: Oral presentation

Implication of Integrin ?5?1 in right ventricular failure associated with pulmonary arterial hypertension

Sarah-Eve Lemay

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - SGLT2 promotes endothelial dysfunction and inflammation induced by plasma from patients with pulmonary hypertension

Hira Muzammel

Replay

Abstract

Slides

Imatinib aggravates pressure-overload-induced right ventricle failure via JNK/Runx2 pathway

Xiaohui Zeng

Replay

Poster

Abstract

Slides

Sustained benefit with seralutinib treatment: Lessons from the open-label extension (OLE) of the TORREY study

Vallerie V. Mclaughlin

Replay

Poster

Abstract

Slides

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study

H. Ardeschir Ghofrani

Replay

Poster

Abstract

Slides

Novel biomarkers for BMPR2 target engagement have significant effects upon mortality in pulmonary arterial hypertension.

Rowena Jones

Replay

Poster

Abstract

Slides

Plasma Proteome Clusters in Pulmonary Hypertension and Their Therapeutic Implications

Athénaïs Boucly

Replay

Abstract

Slides

Exploring biomarkers in CTEPH: prognostic significance and post-PEA dynamics analysis

Alessandra Cuomo

Poster

Abstract

Slides

Implication of Integrin ?5?1 in right ventricular failure associated with pulmonary arterial hypertension

Sarah-eve Lemay

Replay

Abstract

Slides

Right ventricular strain impairment due to hypoxia in patients with COPD

Helga Preiss

Replay

Poster

Abstract

Slides

Effect of eccentric cycling on oxygen uptake and hemodynamics in patients with pulmonary vascular disease.

Julian M?ller

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}